



THE WHITE HOUSE
WASHINGTON

COVID-19 Press Briefing

November 10, 2021



Daily Change in COVID-19 Cases, US

January 22, 2020 – November 08, 2021

TOTAL Cases Reported Since 1/22/20

46,541,113

NEW Cases Reported to CDC on 11/8/21

134,072

Change in 7-Day Case Average


-2.5%

Current 7-Day Case Average (11/2/21 - 11/8/21)

73,313

Prior 7-Day Case Average (10/26/21 - 11/1/21)

75,210



New Admissions of Patients with Confirmed COVID-19, US

August 1, 2020 – November 07, 2021

Patients Currently Hospitalized with COVID on 11/7/21

38,147

New Admissions on 11/7/21

5,086

Peak in New Admissions (1/5/21)

17,949

Change in 7-Day Average of New Admissions


-2.1%

Current 7-Day Average of New Admissions (11/1/21 - 11/7/21)

5,088

Prior 7-Day Average of New Admissions (10/25/21 - 10/31/21)

5,194



Daily Change in COVID-19 Deaths, US

January 22, 2020 – November 08, 2021

TOTAL Deaths Reported Since 1/22/2020

753,564

NEW Deaths Reported to CDC on 11/8/21

1,307

Change in 7-Day Death Average

-11.0%

Current 7-Day Death Average (11/2/21 - 11/8/21)


1,078

Prior 7-Day Death Average (10/26/21 - 11/1/21)

1,211


Forecasted Total Deaths by 11/27/21

765,000 to 789,000



ACIP Recommended Pediatric Vaccines

Average annual deaths, by age group, before implementation of an ACIP recommendation



Recent Advances in Antiviral Therapy for COVID-19



Identification of Vulnerable Targets in the SARS-CoV-2 Replication Cycle




Design Drugs to Inhibit Vulnerable Targets




SARS-CoV-2 Replication Cycle: Targets for Antiviral Therapeutics

Preclinical, Phase 1,
Phase 2/3



SARS-CoV-2 Replication Cycle: Targets for Antiviral Therapeutics

Preclinical, Phase 1,
Phase 2/3



Preclinical

Entry
Inhibitors

Protease
Inhibitors

Polymerase
Inhibitors

Preclinical,
Phase 2, Phase 3




Molnupiravir: Clinical Data Announced Oct. 1, 2021 by Merck and Ridgeback

- Placebo-controlled trial of ~1500 people; DSMB stopped study early at first analysis of 775 people
- End point: prevention of hospitalization or death
- 7% hospitalization in treatment arm and 14% hospitalization or death in placebo arm → 50% decrease
- Placebo – 8 deaths; treatment – 0 deaths



SARS-CoV-2 Replication Cycle: Targets for Antiviral Therapeutics



Paxlovid (Protease Inhibitor + Ritonavir): Clinical Data Announced Nov. 5, 2021 by Pfizer

- Placebo-controlled phase 2/3 trial of ~3,000 people; DSMB stopped study early at scheduled interim analysis of 1,219 people
- Subjects with a laboratory-confirmed diagnosis of SARS-CoV-2 infection with mild-to-moderate symptoms and at least one characteristic/medical condition associated with an increased risk of developing severe illness from COVID-19
- Patients randomized (1:1) to receive Paxlovid or placebo orally every 12 hours for five days.
- **89% reduction in hospitalization or death compared to placebo; 10 deaths in placebo arm, no deaths in treatment arm.**
- Adverse events similar in placebo and treatment arms




U.S. Government Role in Development of Paxlovid

- NIH consultations with Pfizer and referrals to researchers with specific capacities that proved essential
 - Provided novel screening methods for anti-protease activity, helped select the clinical lead
 - *In vitro* testing systems demonstrated the antiviral activity of Paxlovid
 - Animal model testing showed the need for ritonavir boosting
- NIH-led Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) team generated the clinical trial protocol, which Pfizer implemented



Antivirals Are Promising, but Be Sure To Get Vaccinated

- Antivirals are not our first line of defense against COVID-19.
- Get vaccinated to prevent SARS-CoV-2 infection and COVID-19 complications.
- Get a booster shot when it is your turn.





THE WHITE HOUSE
WASHINGTON

WH.GOV